Breast Cancer New Protocol: Neoadj Pembrolizumab + TP for her2+ Breast Cancer Ulas D. Bayraktar, MD 2025-05-05
Breast Cancer New Protocol: Metronomic Capecitabine with Aromatase Inhibitors in Metastatic Breast Cancer Ulas D. Bayraktar, MD 2025-04-22
Breast Cancer New Protocol: Eribulin with Trastuzumab-Pertuzumab in First-Line Breast Cancer Ulas D. Bayraktar, MD 2025-04-22
Breast Cancer New Reference: Trastuzumab Emtansine in HER2-Positive Breast Cancer with Residual Disease Ulas D. Bayraktar, MD 2025-01-24
Breast Cancer New Drug: Datopotamab Deruxtecan for HR+, her2 Neg Breast Cancer Ulas D. Bayraktar, MD 2025-01-20
Breast Cancer New Indication: Adjuvant Ribociclib and Endocrine Therapy in Breast Cancer Ulas D. Bayraktar, MD 2023-06-24
Breast Cancer New Indication: Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (MBC) Ulas D. Bayraktar, MD 2023-06-07
Breast Cancer New Reference: Trastuzumab Deruxtecan for her2-Positive Breast Cancer Ulas D. Bayraktar, MD 2023-05-20
Breast Cancer New Indication: Adjuvant Abemaciclib in HR+ Breast Cancer Ulas D. Bayraktar, MD 2023-05-20
